State of Alaska Department of Revenue Has $63.75 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

State of Alaska Department of Revenue lowered its position in Eli Lilly and Company (NYSE:LLY) by 6.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,374 shares of the company’s stock after selling 6,990 shares during the period. Eli Lilly and Company accounts for 0.8% of State of Alaska Department of Revenue’s portfolio, making the stock its 14th largest holding. State of Alaska Department of Revenue’s holdings in Eli Lilly and Company were worth $63,754,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. JGP Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after buying an additional 16 shares during the period. Cassia Capital Partners LLC grew its holdings in shares of Eli Lilly and Company by 1.8% in the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after buying an additional 17 shares during the period. Walkner Condon Financial Advisors LLC grew its holdings in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after buying an additional 17 shares during the period. Patton Albertson Miller Group LLC grew its holdings in shares of Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after buying an additional 17 shares during the period. Finally, Valley Wealth Managers Inc. grew its holdings in shares of Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after buying an additional 17 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the transaction, the insider now directly owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 195,055 shares of company stock worth $125,254,657 over the last three months. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on LLY. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 20th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $689.52.

Eli Lilly and Company Trading Down 0.0 %

NYSE LLY traded down $0.22 during mid-day trading on Friday, reaching $777.96. 3,209,424 shares of the stock were exchanged, compared to its average volume of 2,972,386. Eli Lilly and Company has a one year low of $334.58 and a one year high of $800.78. The stock has a 50 day simple moving average of $734.06 and a 200-day simple moving average of $637.99. The stock has a market cap of $739.19 billion, a P/E ratio of 134.13, a P/E/G ratio of 1.71 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the company posted $2.09 earnings per share. On average, analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.